Journal of Clinical Oncology
Articles in this Issue
Assessing the current state of cancer survivorship care and barriers at an NCI-designated cancer center.
e13875 Background: Cancer survivorship care is complex and challenging to deliver. The current state of cancer survivorship within the University of Wisco...
SOLTI-2201 ACROSS-TROP2 trial: A phase II study to identify predictive biomarkers of sacituzumab govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer.
TPS1123 Background: Sacituzumab Govitecan (SG) is a TROP2-directed antibody-drug conjugate (ADC) linked to a topoisomerase I inhibitor via a hydrolysable...
A phase 2 trial to evaluate the efficacy and safety of WZTL-002, a third-generation anti-CD19 CAR T-cell therapy, in patients with relapsed or refractory large B-cell lymphoma (ENABLE-2).
TPS7084 Background: Autologous chimeric antigen receptor (CAR) T-cells directed against CD19 are a standard of care for relapsed or refractory (r/r) large...
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.
TPS3644 Background: Currently, there are no biomarkers validated prospectively in randomized studies for resected colon cancer (CC) to determine need for...
Response and long-term survival in stage IV lung adenocarcinoma as predicted by serial 3-D explant analyses with molecular correlates: Tumor biology as evolutionary biology.
e20545 Background: The principles of evolutionary biology have been the subject of intense investigation in cancer. The TraceRx program conducts serial bi...
Analyzing the relationship between glutaminase expression and features of the immune tumor microenvironment in epithelial ovarian cancer using imaging mass cytometry.
5560 Background: Immunotherapy has thus far shown limited efficacy in epithelial ovarian cancer, likely driven in part by an immune suppressive tumor micr...
Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study.
11500 Background: TGCT is a rare, locally aggressive mesenchymal neoplasm, driven by the overproduction of colony-stimulating factor 1 (CSF-1), and is oft...
Toward manipulating sex hormones to modulate the adaptive antitumor immune response in liver cancer.
e16246 Background: The incidence and mortality of hepatocellular carcinoma (HCC) is three to seven times greater in men than women after accounting for kn...
A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01.
3123 Background: ATG-037 is a highly potent oral small molecule inhibitor of CD73. STAMINA-01 is an open-label, first-in-human, phase 1/1b study (NCT05205...
m6A-methylated lncRNAs to facilitate keratinocyte pyroptosis and to spark cutaneous toxicities associated with anticancer treatments.
e24078 Background: Cutaneous toxicities are common adverse effects (AEs) associated with antineoplastic therapies, including cytotoxic chemotherapies, tar...
Efficacy and safety of anlotinib combined with ¹³¹I therapy in the treatment of distant metastatic differentiated thyroid cancer: A single-arm, phase II clinical study.
e18133 Background: Distant metastatic differentiated thyroid cancer (DTC) commonly responds poorly to radioiodine ( 131 I) treatme...
Prognostic significance of blood-based multi-cancer detection in circulating tumor DNA (ctDNA): 5-year outcomes analysis.
101 Background: In the case-control Circulating Cell-free Genome Atlas (CCGA) study (NCT02889978), a multi-cancer early detection (MCED) test was develope...
Quantum mechanics–based multi-tensor AI/ML discovery and validation of actionable and mechanistically interpretable whole-transcriptome predictors of survival in response to immunotherapy from real-world clinical trial data.
2621 Background: Prediction in cancer remains limited, and 90% of drugs continue to fail trials and post-market validation. The entire multi-ome affects t...
The efficacy and safety of donafenib combined with anti–PD-1 antibody plus transarterial chemoembolization (TACE) as first-line treatment for patients (pts) with hepatocellular carcinoma (HCC): A retrospective study.
e16219 Background: Transarterial chemoembolization (TACE), anti-angiogenic therapy, immune checkpoint inhibitor (ICI) therapy, and their combination strat...
Multiple myeloma as a predictor of in-hospital outcomes in ESRD patients: A nationwide analysis.
e23068 Background: Multiple Myeloma (MM) has a 3-year survival rate of about 60% in frail patients. It is a precursor to acute kidney injury and chronic k...
METANOVA: A phase II trial of metastasis-directed radiotherapy for de novo oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial.
TPS5128 Background: Men with de novo oligometastatic hormone-sensitive prostate cancer (omHSPC) represent a unique subgroup where metastasis-directed radi...
The association of medical mistrust (MM) to medical decision-making (MDM) preferences in cancer (CA) patients (pts).
e13790 Background: Medical mistrust (MM) is associated with adverse health outcomes, but relatively few studies have assessed MM among CA pts. CA pts face...
Upgrade rates and treatment recommendations for patients with pleomorphic and florid lobular carcinoma in situ.
e12563 Background: Long term follow up data is limited regarding the natural history of patients diagnosed with Pleomorphic Lobular Carcinoma in situ (PLC...
Safety, tolerance, and preliminary efficacy of autologous tumor-infiltrating lymphocytes (TILs) LM103 injection in Chinese patients with advanced melanoma and an exploration of the factors influencing the therapeutic effect.
e21508 Background: The safety and efficacy of TIL in Asian patients, mainly with acral subtypes, remain largely unknown. Therefore, we designed and implem...
Is metastatic cancer curable? A survey of medical oncologists.
12112 Background: More patients with metastatic cancer are living longer due to treatment advances like immune checkpoint inhibitors and targeted therapie...
Hepatic arterial infusion chemotherapy combined with donafenib and tislelizumab versus transcatheter chemoembolization alone for hepatocellular carcinoma: A propensity score matching study.
4094 Background: Although tyrosine kinase inhibitors combined with PD-1/L1 inhibitors have been established as first-line treatment for advanced hepatocel...
Exploring the evolving therapeutic landscape of stage IV lung squamous cell carcinoma: A 13-year single center experience.
e20569 Background: Several seminal trials have reshaped the standard treatment of stage IV lung squamous cell carcinoma (SCC) over the last decade and int...
A multicenter, open-label, single-arm phase I/II study to assess the efficacy and safety of WSD0922-FU in patients with EGFR C797Sm+ advanced non-small cell lung cancer (NSCLC) in China (NCT06631989).
TPS8661 Background: Although 3rd-generation EGFR TKIs, such as Osimertinib, Almonertinib, Furmonertinib, Befotertinib etc. are highly effective in front-l...
Comprehensive germline analysis in young adults of Latin American descent with early-onset cancer.
e22600 Background: Approximately 8% of adult cancer patients carry a pathogenic germline variant (PGV), and 35% have variants of uncertain significance (V...
Perioperative immunotherapy for stage II-III NSCLC patients: A retrospective real-world analysis.
e20048 Background: Stage II-III non-small cell lung cancer (NSCLC) is often considered curable. However, in the perioperative chemotherapy era, the median...